Jianjun Mu

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 206 citations · Full text

Molecular Pharmacology, Hypertension, Resistant Hypertension +9

Down-regulation of lncRNA KCNQ1OT1 protects against myocardial ischemia/reperfusion injury following acute myocardial infarction

Xin Li, Yingnan Dai, Shujun Yan et al. · Biochemical and Biophysical Research Communications · 2017 · 149 citations

Molecular Physiology, Cardiovascular Disease, Cell Signaling +10

Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial

Jiang He, Nanxiang Ouyang, Xiaofan Guo et al. · The Lancet · 2023 · 120 citations

Hypertension, Cardiovascular Disease, Health Policy +10

Association of Blood Pressure Trajectories in Early Life with Subclinical Renal Damage in Middle Age

Wenling Zheng, Jianjun Mu, Chao Chu et al. · Journal of the American Society of Nephrology · 2018 · 97 citations · Full text

Cloning and RNAi‐mediated functional characterization of <i>MaLac2</i> of the pine sawyer, <i>Monochamus alternatus</i>

Bin Niu, Weifeng Shen, Y. Liu et al. · Insect Molecular Biology · 2008 · 92 citations

Essential Phenoloxidase, Engineering, Genetics +22